State-of-the-Art Approaches to Heterologous Expression of Bispecific Antibodies Targeting Solid Tumors
Open Access
- 22 September 2023
- journal article
- review article
- Published by Pleiades Publishing Ltd in Biochemistry (Moscow)
- Vol. 88 (9) , 1215-1231
Abstract
Bispecific antibodies (bsAbs) are some of the most promising biotherapeutics due to the versatility provided by their structure and functional features. bsAbs simultaneously bind two antigens or two epitopes on the same antigen. Moreover, they are capable of directing immune effector cells to cancer cells and delivering various compounds (radionuclides, toxins, and immunologic agents) to the target cells, thus offering a broad spectrum of clinical applications. Current review is focused on the technologies used in bsAb engineering, current progress and prospects of these antibodies, and selection of various heterologous expression systems for bsAb production. We also discuss the platforms development of bsAbs for the therapy of solid tumors.Keywords
This publication has 98 references indexed in Scilit:
- Production of functional antibody fragments in a vesicle-based eukaryotic cell-free translation systemJournal of Biotechnology, 2013
- Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodiesmAbs, 2012
- A Multi-Omics Analysis of Recombinant Protein Production in Hek293 CellsPLOS ONE, 2012
- A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigensmAbs, 2011
- Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodiesProceedings of the National Academy of Sciences, 2011
- Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering EffectsJournal of Biological Chemistry, 2010
- Enhancement of cell proliferation in various mammalian cell lines by gene insertion of a cyclin-dependent kinase homologBMC Biotechnology, 2007
- Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulinNature Biotechnology, 2007
- Improved Pharmacokinetics of Recombinant Bispecific Antibody Molecules by Fusion to Human Serum AlbuminJournal of Biological Chemistry, 2007
- An efficient route to human bispecific IgGNature Biotechnology, 1998